The gut microbiota as a therapeutic target in ibd and metabolic disease: A role for the bile acid receptors fxr and tgr5

Microorganisms

Volumn 3, Issue 4, 2015, Pages 641-666

  Baars, Annemarie ^a   Oosting, Annemarie ^a   Knol, Jan ^a,b   Garssen, Johan ^a,c   van Bergenhenegouwen, Jeroen ^a,c  

^a DANONE NUTRICIA RESEARCH   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Bile acid dysregulation; Dysbiosis; FXR; Gut microbiota; Inflammatory bowel disease; Metabolic disease; Probiotics; TGR5

Indexed keywords

EID: 85040449296     PISSN: None     EISSN: 20762607     Source Type: Journal    
DOI: 10.3390/microorganisms3040641     Document Type: Review

References (145)

1. Scholtens, P.A.; Oozeer, R.; Martin, R.; Amor, K.B.; Knol, J. The early settlers: Intestinal microbiology in early life. Annu. Rev. Food Sci. Technol.2012, 3, 425–447.
2. Koenig, J.E.; Spor, A.; Scalfone, N.; Fricker, A.D.; Stombaugh, J.; Knight, R.; Angenent, L.T.; Ley, R.E. Succession of microbial consortia in the developing infant gut microbiome. Proc. Nat. Acad. Sci. USA 2011, 108, 4578–4585.
3. Zoetendal, E.G.; Rajilic-Stojanovic, M.; de Vos, W.M. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008, 57, 1605–1615.
4. Koren, O.; Knights, D.; Gonzalez, A.; Waldron, L.; Segata, N.; Knight, R.; Huttenhower, C.; Ley, R.E. A guide to enterotypes across the human body: Meta-analysis of microbial community structures in human microbiome datasets. PLoS Comput. Biol. 2013, 9, doi:10.1371/journal.pcbi.1002863 e1002863.
5. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K.S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.; Yamada, T.; et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464, 59–65.
6. Backhed, F.; Fraser, C.M.; Ringel, Y.; Sanders, M.E.; Sartor, R.B.; Sherman, P.M.; Versalovic, J.; Young, V.; Finlay, B.B. Defining a healthy human gut microbiome: Current concepts, future directions, and clinical applications. Cell Host Microbe 2012, 12, 611–622.
7. Ottman, N.; Smidt, H.; de Vos, W.M.; Belzer, C. The function of our microbiota: Who is out there and what do they do? Front. Cell. Infect. Microbiol. 2012, 2, 104.
8. Zeissig, S.; Blumberg, R.S. Life at the beginning: Perturbation of the microbiota by antibiotics in early life and its role in health and disease. Nature Immunol. 2014, 15, 307–310.
9. Mshvildadze, M.; Neu, J. The infant intestinal microbiome: Friend or foe? Early Hum. Dev. 2010, 86, 67–71.
10. Walujkar, S.A.; Dhotre, D.P.; Marathe, N.P.; Lawate, P.S.; Bharadwaj, R.S.; Shouche, Y.S. Characterization of bacterial community shift in human ulcerative colitis patients revealed by illumina based 16s rrna gene amplicon sequencing. Gut Pathog. 2014, 6, 22–33.
11. Sartor, R.B. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology 2010, 139, 1816–1819.
12. Henao-Mejia, J.; Elinav, E.; Thaiss, C.A.; Licona-Limon, P.; Flavell, R.A. Role of the intestinal microbiome in liver disease. J. Autoimmun. 2013, 46, 66–73.
13. Penders, J.; Gerhold, K.; Stobberingh, E.E.; Thijs, C.; Zimmermann, K.; Lau, S.; Hamelmann, E. Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood. J. Allergy Clin. Immunol. 2013, 132, 601–607.
14. Giongo, A.; Gano, K.A.; Crabb, D.B.; Mukherjee, N.; Novelo, L.L.; Casella, G.; Drew, J.C.; Ilonen, J.; Knip, M.; Hyoty, H.; et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J. 2011, 5, 82–91.
15. Karlsson, F.H.; Tremaroli, V.; Nookaew, I.; Bergstrom, G.; Behre, C.J.; Fagerberg, B.; Nielsen, J.; Backhed, F. Gut metagenome in european women with normal, impaired and diabetic glucose control. Nature 2013, 498, 99–103.
16. Turnbaugh, P.J.; Hamady, M.; Yatsunenko, T.; Cantarel, B.L.; Duncan, A.; Ley, R.E.; Sogin, M.L.; Jones, W.J.; Roe, B.A.; Affourtit, J.P.; et al. A core gut microbiome in obese and lean twins. Nature 2009, 457, 480–484.
17. Hill, D.A.; Artis, D. Intestinal bacteria and the regulation of immune cell homeostasis. Annu. Rev. Immunol. 2010, 28, 623–667.
18. Round, J.L.; Mazmanian, S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nature Rev. Immunol. 2009, 9, 313–323.
19. Hooper, L.V.; Littman, D.R.; Macpherson, A.J. Interactions between the microbiota and the immune system. Science 2012, 336, 1268–1273.
20. Chinen, T.; Rudensky, A.Y. The effects of commensal microbiota on immune cell subsets and inflammatory responses. Immunol. Rev. 2012, 245, 45–55.
21. Ma, H.; Patti, M.E. Bile acids, obesity, and the metabolic syndrome. Best Pract. Res. Clin. Gastroenterol. 2014, 28, 573–583.
22. Charach, G.; Grosskopf, I.; Rabinovich, A.; Shochat, M.; Weintraub, M.; Rabinovich, P. The association of bile acid excretion and atherosclerotic coronary artery disease. Ther. Adv. Gastroenterol. 2011, 4, 95–101.
23. Duboc, H.; Rajca, S.; Rainteau, D.; Benarous, D.; Maubert, M.A.; Quervain, E.; Thomas, G.; Barbu, V.; Humbert, L.; Despras, G.; et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013, 62, 531–539.
24. Abrahamse, E.; Minekus, M.; van Aken, G.A.; van de Heijning, B.; Knol, J.; Bartke, N.; Oozeer, R.; van der Beek, E.M.; Ludwig, T. Development of the digestive system—Experimental challenges and approaches of infant lipid digestion. Food Dig. 2012, 3, 63–77.
25. De Aguiar Vallim, T.Q.; Tarling, E.J.; Edwards, P.A. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013, 17, 657–669.
26. Brestoff, J.R.; Artis, D. Commensal bacteria at the interface of host metabolism and the immune system. Nature Immunol. 2013, 14, 676–684.
27. Kuipers, F.; Bloks, V.W.; Groen, A.K. Beyond intestinal soap—Bile acids in metabolic control. Nature Rev. Endocrinol. 2014, 10, 488–498.
28. Hofmann, A.F. The enterohepatic circulation of bile acids in mammals: Form and functions. Front. Biosci. 2009, 14, 2584–2598.
29. Bortolini, O.; Medici, A.; Poli, S. Biotransformations on steroid nucleus of bile acids. Steroids 1997, 62, 564–577.
30. Sayin, S.I.; Wahlstrom, A.; Felin, J.; Jantti, S.; Marschall, H.U.; Bamberg, K.; Angelin, B.; Hyotylainen, T.; Oresic, M.; Backhed, F. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013, 17, 225–235.
31. Joyce, S.A.; MacSharry, J.; Casey, P.G.; Kinsella, M.; Murphy, E.F.; Shanahan, F.; Hill, C.; Gahan, C.G. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc. Nat. Acad. Sci. USA 2014, 111, 7421–7426.
32. Ridlon, J.M.; Kang, D.J.; Hylemon, P.B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 2006, 47, 241–259.
33. Begley, M.; Gahan, C.G.; Hill, C. The interaction between bacteria and bile. FEMS Microbiol. Rev. 2005, 29, 625–651.
34. Sonoda, J.; Pei, L.; Evans, R.M. Nuclear receptors: Decoding metabolic disease. FEBS Sett. 2008, 582, 2–9.
35. Forman, B.M.; Goode, E.; Chen, J.; Oro, A.E.; Bradley, D.J.; Perlmann, T.; Noonan, D.J.; Burka, L.T.; McMorris, T.; Lamph, W.W.; et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81, 687–693.
36. Wang, H.; Chen, J.; Hollister, K.; Sowers, L.C.; Forman, B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 1999, 3, 543–553.
37. Matsubara, T.; Li, F.; Gonzalez, F.J. FXR signaling in the enterohepatic system. Mol. Cell. Endocrinol. 2013, 368, 17–29.
38. Rao, A.; Haywood, J.; Craddock, A.L.; Belinsky, M.G.; Kruh, G.D.; Dawson, P.A. The organic solute transporter alpha-beta, ostalpha-ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc. Nat. Acad. Sci. USA 2008, 105, 3891–3896.
39. Zhu, Y.; Li, F.; Guo, G.L. Tissue-specific function of farnesoid X receptor in liver and intestine. Pharmacol. Res.2011, 63, 259–265.
40. Chiang, J.Y. Bile acids: Regulation of synthesis. J. Lipid Res. 2009, 50, 1955–1966.
41. Kim, I.; Ahn, S.H.; Inagaki, T.; Choi, M.; Ito, S.; Guo, G.L.; Kliewer, S.A.; Gonzalez, F.J. Differential regulation of bile acid homeostasis by the farnesoid x receptor in liver and intestine. J. Lipid Res. 2007, 48, 2664–2672.
42. Degirolamo, C.; Rainaldi, S.; Bovenga, F.; Murzilli, S.; Moschetta, A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 2014, 7, 12–18.
43. Renga, B.; Mencarelli, A.; Cipriani, S.; D’Amore, C.; Carino, A.; Bruno, A.; Francisci, D.; Zampella, A.; Distrutti, E.; Fiorucci, S. The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation. PloS ONE 2013, 8, doi: 10.1371/journal.pone.0054472
44. Modica, S.; Cariello, M.; Morgano, A.; Gross, I.; Vegliante, M.C.; Murzilli, S.; Salvatore, L.; Freund, J.N.; Sabba, C.; Moschetta, A. Transcriptional regulation of the intestinal nuclear bile acid farnesoid x receptor (FXR) by the caudal-related homeobox 2 (CDX2). J. Biol. Chem. 2014, 289, 28421–28432.
45. Kazumori, H.; Ishihara, S.; Rumi, M.A.; Kadowaki, Y.; Kinoshita, Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in barrett’s epithelium. Gut 2006, 55, 16–25.
46. Vavassori, P.; Mencarelli, A.; Renga, B.; Distrutti, E.; Fiorucci, S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 2009, 183, 6251–6261.
47. Wang, Y.-D.; Chen, W.-D.; Moore, D.D.; Huang, W. FXR: A metabolic regulator and cell protector. Cell Res. 2008, 18, 1087–1095.
48. Lefebvre, P.; Cariou, B.; Lien, F.; Kuipers, F.; Staels, B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 2009, 89, 147–191.
49. Zhang, Y.; Lee, F.Y.; Barrera, G.; Lee, H.; Vales, C.; Gonzalez, F.J.; Willson, T.M.; Edwards, P.A. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Nat. Acad. Sci. USA 2006, 103, 1006–1011.
50. Ma, Y.; Huang, Y.; Yan, L.; Gao, M.; Liu, D. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm. Res. 2013, 30, 1447–1457.
51. Cariou, B.; van Harmelen, K.; Duran-Sandoval, D.; van Dijk, T.H.; Grefhorst, A.; Abdelkarim, M.; Caron, S.; Torpier, G.; Fruchart, J.-C.; Gonzalez, F.J. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 2006, 281, 11039–11049.
52. Savage, D.B.; Petersen, K.F.; Shulman, G.I. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 2007, 87, 507–520.
53. Watanabe, M.; Horai, Y.; Houten, S.M.; Morimoto, K.; Sugizaki, T.; Arita, E.; Mataki, C.; Sato, H.; Tanigawara, Y.; Schoonjans, K. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J. Biol. Chem. 2011, 286, 26913–26920.
54. Zhang, Y.; Ge, X.; Heemstra, L.A.; Chen, W.-D.; Xu, J.; Smith, J.L.; Ma, H.; Kasim, N.; Edwards, P.A.; Novak, C.M. Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice. Mol. Endocrinol. 2012, 26, 272–280.
55. Prawitt, J.; Abdelkarim, M.; Stroeve, J.H.; Popescu, I.; Duez, H.; Velagapudi, V.R.; Dumont, J.; Bouchaert, E.; Van Dijk, T.H.; Lucas, A. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 2011, 60, 1861–1871.
56. Watanabe, M.; Houten, S.M.; Mataki, C.; Christoffolete, M.A.; Kim, B.W.; Sato, H.; Messaddeq, N.; Harney, J.W.; Ezaki, O.; Kodama, T. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006, 439, 484–489.
57. Stroeve, J.H.; Brufau, G.; Stellaard, F.; Gonzalez, F.J.; Staels, B.; Kuipers, F. Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice. Lab. Investig. 2010, 90, 1457–1467.
58. Berg, R.D. Bacterial translocation from the gastrointestinal tract. Trends Microbiol. 1995, 3, 149–154.
59. Slocum, M.M.; Sittig, K.M.; Specian, R.D.; Deitch, E.A. Absence of intestinal bile promotes bacterial translocation. Am. Surg. 1992, 58, 305–310.
60. Ding, J.W.; Andersson, R.; Soltesz, V.; Willen, R.; Bengmark, S. The role of bile and bile acids in bacterial translocation in obstructive jaundice in rats. Eur. Surg. Res. 1993, 25, 11–19.
61. Lorenzo-Zuniga, V.; Bartoli, R.; Planas, R.; Hofmann, A.F.; Vinado, B.; Hagey, L.R.; Hernandez, J.M.; Mane, J.; Alvarez, M.A.; Ausina, V.; et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 2003, 37, 551–557.
62. Cremers, C.M.; Knoefler, D.; Vitvitsky, V.; Banerjee, R.; Jakob, U. Bile salts act as effective protein-unfolding agents and instigators of disulfide stress in vivo. Proc. Nat. Acad. Sci. USA 2014, 111, 1610–1619.
63. Inagaki, T.; Moschetta, A.; Lee, Y.K.; Peng, L.; Zhao, G.; Downes, M.; Yu, R.T.; Shelton, J.M.; Richardson, J.A.; Repa, J.J.; et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Nat. Acad. Sci. USA 2006, 103, 3920–3925.
64. Hofmann, A.F.; Eckmann, L. How bile acids confer gut mucosal protection against bacteria. Proc. Nat. Acad. Sci. USA 2006, 103, 4333–4334.
65. Maran, R.R.; Thomas, A.; Roth, M.; Sheng, Z.; Esterly, N.; Pinson, D.; Gao, X.; Zhang, Y.; Ganapathy, V.; Gonzalez, F.J.; et al. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharmacol. Exp. Ther. 2009, 328, 469–477.
66. Bailey, A.M.; Zhan, L.; Maru, D.; Shureiqi, I.; Pickering, C.R.; Kiriakova, G.; Izzo, J.; He, N.; Wei, C.; Baladandayuthapani, V.; et al. FXR silencing in human colon cancer by DNA methylation and KRAS signaling. Am. J. Physiol. 2014, 306, G48–G58.
67. Glass, C.K.; Ogawa, S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nature rev. Immunol. 2006, 6, 44–55.
68. Pascual, G.; Fong, A.L.; Ogawa, S.; Gamliel, A.; Li, A.C.; Perissi, V.; Rose, D.W.; Willson, T.M.; Rosenfeld, M.G.; Glass, C.K. A sumoylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 2005, 437, 759–763.
69. Balasubramaniyan, N.; Luo, Y.; Sun, A.Q.; Suchy, F.J. Sumoylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes. J. Biol. Chem. 2013, 288, 13850–13862.
70. Wang, Y.D.; Chen, W.D.; Wang, M.; Yu, D.; Forman, B.M.; Huang, W. Farnesoid X receptor antagonizes nuclear factor KB in hepatic inflammatory response. Hepatology 2008, 48, 1632–1643.
71. Gadaleta, R.M.; van Erpecum, K.J.; Oldenburg, B.; Willemsen, E.C.; Renooij, W.; Murzilli, S.; Klomp, L.W.; Siersema, P.D.; Schipper, M.E.; Danese, S.; et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011, 60, 463–472.
72. Gadaleta, R.M.; Oldenburg, B.; Willemsen, E.C.; Spit, M.; Murzilli, S.; Salvatore, L.; Klomp, L.W.; Siersema, P.D.; van Erpecum, K.J.; van Mil, S.W. Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-KB signaling in the intestine. Biochim. Biophys. Acta 2011, 1812, 851–858.
73. Dijkstra, G.; Hommes, D.W.; de Jong, D.J.; Stokkers, P.C.; Verspaget, H.W.; Weersma, R.K.; van der Woude, C.J.; Stapelbroek, J.M.; Schipper, M.E.I.; Wijmenga, C.; et al. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. PloS ONE 2011, 6, doi:10.1371/journal.pone.0023745.
74. Raufman, J.P.; Chen, Y.; Zimniak, P.; Cheng, K. Deoxycholic acid conjugates are muscarinic cholinergic receptor antagonists. Pharmacology 2002, 65, 215–221.
75. Chen, X.; Yang, D.; Shen, W.; Dong, H.F.; Wang, J.M.; Oppenheim, J.J.; Howard, M.Z. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. Inflamm. Res. 2000, 49, 744–755.
76. Kawamata, Y.; Fujii, R.; Hosoya, M.; Harada, M.; Yoshida, H.; Miwa, M.; Fukusumi, S.; Habata, Y.; Itoh, T.; Shintani, Y.; et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 2003, 278, 9435–9440.
77. Maruyama, T.; Miyamoto, Y.; Nakamura, T.; Tamai, Y.; Okada, H.; Sugiyama, E.; Nakamura, T.; Itadani, H.; Tanaka, K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 2002, 298, 714–719.
78. Maruyama, T.; Tanaka, K.; Suzuki, J.; Miyoshi, H.; Harada, N.; Nakamura, T.; Miyamoto, Y.; Kanatani, A.; Tamai, Y. Targeted disruption of G protein-coupled bile acid receptor 1 (GPBAR1/ M-BAR) in mice. J. Endocrinol. 2006, 191, 197–205.
79. Li, T.; Holmstrom, S.R.; Kir, S.; Umetani, M.; Schmidt, D.R.; Kliewer, S.A.; Mangelsdorf, D.J. The G protein-coupled bile acid receptor, tgr5, stimulates gallbladder filling. Mol. Endocrinol. 2011, 25, 1066–1071.
80. Duboc, H.; Tache, Y.; Hofmann, A.F. The bile acid TGR5 membrane receptor: From basic research to clinical application. Dig. Liv. Dis. 2014, 46, 302–312.
81. Thomas, C.; Gioiello, A.; Noriega, L.; Strehle, A.; Oury, J.; Rizzo, G.; Macchiarulo, A.; Yamamoto, H.; Mataki, C.; Pruzanski, M. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009, 10, 167–177.
82. Kumar, D.P.; Rajagopal, S.; Mahavadi, S.; Mirshahi, F.; Grider, J.R.; Murthy, K.S.; Sanyal, A.J. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. Biochem. Biophys. Res. Commun. 2012, 427, 600–605.
83. Pols, T.W.; Nomura, M.; Harach, T.; Lo Sasso, G.; Oosterveer, M.H.; Thomas, C.; Rizzo, G.; Gioiello, A.; Adorini, L.; Pellicciari, R.; et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011, 14, 747–757.
84. Kida, T.; Tsubosaka, Y.; Hori, M.; Ozaki, H.; Murata, T. Bile acid receptor TGR5 agonism induces no production and reduces monocyte adhesion in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1663–1669.
85. Cipriani, S.; Mencarelli, A.; Chini, M.G.; Distrutti, E.; Renga, B.; Bifulco, G.; Baldelli, F.; Donini, A.; Fiorucci, S. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PloS ONE 2011, 6, doi:10.1371/journal.pone.0025637.
86. Yoneno, K.; Hisamatsu, T.; Shimamura, K.; Kamada, N.; Ichikawa, R.; Kitazume, M.T.; Mori, M.; Uo, M.; Namikawa, Y.; Matsuoka, K.; et al. TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in crohn’s disease. Immunology 2013, 139, 19–29.
87. Yoshimura, T.; Kurita, C.; Nagao, T.; Usami, E.; Nakao, T.; Watanabe, S.; Kobayashi, J.; Yamazaki, F.; Tanaka, H.; Inagaki, N.; et al. Inhibition of tumor necrosis factor-α and interleukin-1-β production by β-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Pharmacology 1997, 54, 144–152.
88. Miyazaki-Anzai, S.; Masuda, M.; Levi, M.; Keenan, A.L.; Miyazaki, M. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis. PloS ONE 2014, 9, doi:10.1371/journal.pone.0108270.
89. Wall, E.A.; Zavzavadjian, J.R.; Chang, M.S.; Randhawa, B.; Zhu, X.; Hsueh, R.C.; Liu, J.; Driver, A.; Bao, X.R.; Sternweis, P.C.; et al. Suppression of LPS-induced TNF-α production in macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci. Signal. 2009, 2, doi:10.1126/scisignal.2000202.
90. Lou, G.; Ma, X.; Fu, X.; Meng, Z.; Zhang, W.; Wang, Y.D.; Van Ness, C.; Yu, D.; Xu, R.; Huang, W. GPBAR1/TGR5 mediates bile acid-induced cytokine expression in murine kupffer cells. PloS ONE 2014, 9, doi:10.1371/journal.pone.0093567
91. Pean, N.; Doignon, I.; Garcin, I.; Besnard, A.; Julien, B.; Liu, B.; Branchereau, S.; Spraul, A.; Guettier, C.; Humbert, L.; et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology 2013, 58, 1451–1460.
92. Wang, Y.D.; Chen, W.D.; Yu, D.; Forman, B.M.; Huang, W. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated b cells (Nf-KB) in mice. Hepatology 2011, 54, 1421–1432.
93. Perino, A.; Pols, T.W.; Nomura, M.; Stein, S.; Pellicciari, R.; Schoonjans, K. TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation. J. Clin.Investig. 2014, 124, 5424–5436.
94. Li, T.; Chiang, J.Y. Bile acid signaling in liver metabolism and diseases. J. Lipid 2011, 2012, doi:10.1155/2012/754067.
95. Schaap, F.G.; Trauner, M.; Jansen, P.L. Bile acid receptors as targets for drug development. Nature Rev. Gastroenterol. Hepatol. 2014, 11, 55–67.
96. Sokol, H.; Seksik, P.; Rigottier-Gois, L.; Lay, C.; Lepage, P.; Podglajen, I.; Marteau, P.; Dore, J. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm. Bowel Dis. 2006, 12, 106–111.
97. Li, Q.; Wang, C.; Tang, C.; Li, N.; Li, J. Molecular-phylogenetic characterization of the microbiota in ulcerated and non-ulcerated regions in the patients with crohn’s disease. PloS ONE 2012, 7, doi:10.1371/journal.pone.0034939.
98. Sokol, H.; Seksik, P.; Furet, J.P.; Firmesse, O.; Nion-Larmurier, I.; Beaugerie, L.; Cosnes, J.; Corthier, G.; Marteau, P.; Dore, J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis. 2009, 15, 1183–1189.
99. Morgan, X.C.; Tickle, T.L.; Sokol, H.; Gevers, D.; Devaney, K.L.; Ward, D.V.; Reyes, J.A.; Shah, S.A.; LeLeiko, N.; Snapper, S.B.; et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012, 13, R79.
100. Jones, B.V.; Begley, M.; Hill, C.; Gahan, C.G.; Marchesi, J.R. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc. Nat. Acad. Sci. USA 2008, 105, 13580–13585.
101. Labbe, A.; Ganopolsky, J.G.; Martoni, C.J.; Prakash, S.; Jones, M.L. Bacterial bile metabolising gene abundance in crohn’s, ulcerative colitis and type 2 diabetes metagenomes. PloS ONE 2014, 9, doi:10.1371/journal.pone.0115175.
102. Attinkara, R.; Mwinyi, J.; Truninger, K.; Regula, J.; Gaj, P.; Rogler, G.; Kullak-Ublick, G.A.; Eloranta, J.J.; Swiss, I.B.D.C.S.G. Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor fxr, with inflammatory bowel disease. BMC Res. Note 2012, 5, 461.
103. Bruce, K.D.; Hanson, M.A. The developmental origins, mechanisms, and implications of metabolic syndrome. J. Nutr 2010, 140, 648–652.
104. Godfrey, K.M. Maternal regulation of fetal development and health in adult life. Eur. J. Obstet. Gynecol. Reprod. Biol. 1998, 78, 141–150.
105. Barker, D.J.; Gluckman, P.D.; Godfrey, K.M.; Harding, J.E.; Owens, J.A.; Robinson, J.S. Fetal nutrition and cardiovascular disease in adult life. Lancet 1993, 341, 938–941.
106. Cleal, J.K.; Poore, K.R.; Boullin, J.P.; Khan, O.; Chau, R.; Hambidge, O.; Torrens, C.; Newman, J.P.; Poston, L.; Noakes, D.E.; et al. Mismatched pre-and postnatal nutrition leads to cardiovascular dysfunction and altered renal function in adulthood. Proc. Nat. Acad. Sci. USA 2007, 104, 9529–9533.
107. Vickers, M.H.; Breier, B.H.; Cutfield, W.S.; Hofman, P.L.; Gluckman, P.D. Fetal origins of hyperphagia, obesity, and hypertension and postnatal amplification by hypercaloric nutrition. Am. J. Physiol.. Endocrinol. Metab. 2000, 279, 83–87.
108. DiBaise, J.K.; Zhang, H.; Crowell, M.D.; Krajmalnik-Brown, R.; Decker, G.A.; Rittmann, B.E. Gut microbiota and its possible relationship with obesity. Mayo Clin. Proc. 2008, 83, 460–469.
109. Hooper, L.V.; Wong, M.H.; Thelin, A.; Hansson, L.; Falk, P.G.; Gordon, J.I. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001, 291, 881–884.
110. Ley, R.E.; Turnbaugh, P.J.; Klein, S.; Gordon, J.I. Microbial ecology: Human gut microbes associated with obesity. Nature 2006, 444, 1022–1023.
111. Tremaroli, V.; Bäckhed, F. Functional interactions between the gut microbiota and host metabolism. Nature 2012, 489, 242–249.
112. Walters, W.A.; Xu, Z.; Knight, R. Meta-analyses of human gut microbes associated with obesity and ibd. FEBS Lett. 2014, 588, 4223–4233.
113. Bervoets, L.; van Hoorenbeeck, K.; Kortleven, I.; van Noten, C.; Hens, N.; Vael, C.; Goossens, H.; Desager, K.N.; Vankerckhoven, V. Differences in gut microbiota composition between obese and lean children: A cross-sectional study. Gut Pathog. 2013, 5, 1–10.
114. Tims, S.; Derom, C.; Jonkers, D.M.; Vlietinck, R.; Saris, W.H.; Kleerebezem, M.; de Vos, W.M.; Zoetendal, E.G. Microbiota conservation and bmi signatures in adult monozygotic twins. ISME J. 2013, 7, 707–717.
115. Duncan, S.H.; Lobley, G.E.; Holtrop, G.; Ince, J.; Johnstone, A.M.; Louis, P.; Flint, H.J. Human colonic microbiota associated with diet, obesity and weight loss. Int. J. Obes. 2008, 32, 1720–1724.
116. Schwiertz, A.; Taras, D.; Schafer, K.; Beijer, S.; Bos, N.A.; Donus, C.; Hardt, P.D. Microbiota and scfa in lean and overweight healthy subjects. Obesity 2010, 18, 190–195.
117. Cotillard, A.; Kennedy, S.P.; Kong, L.C.; Prifti, E.; Pons, N.; Le Chatelier, E.; Almeida, M.; Quinquis, B.; Levenez, F.; Galleron, N.; et al. Dietary intervention impact on gut microbial gene richness. Nature 2013, 500, 585–588.
118. Le Chatelier, E.; Nielsen, T.; Qin, J.; Prifti, E.; Hildebrand, F.; Falony, G.; Almeida, M.; Arumugam, M.; Batto, J.M.; Kennedy, S.; et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013, 500, 541–546.
119. Lepage, P.; Leclerc, M.C.; Joossens, M.; Mondot, S.; Blottiere, H.M.; Raes, J.; Ehrlich, D.; Dore, J. A metagenomic insight into our gut's microbiome. Gut 2013, 62, 146–158.
120. Damms-Machado, A.; Mitra, S.; Schollenberger, A.E.; Kramer, K.M.; Meile, T.; Königsrainer, A.; Huson, D.H.; Bischoff, S.C. Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption. Bio. Med. Res. Int. 2015, 2015.
121. Flynn, C.R.; Albaugh, V.L.; Cai, S.; Cheung-Flynn, J.; Williams, P.E.; Brucker, R.M.; Bordenstein, S.R.; Guo, Y.; Wasserman, D.H.; Abumrad, N.N. Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery. Nature Commun. 2015, 6. doi:10.1038/ncomms8715.
122. Ryan, K.K.; Tremaroli, V.; Clemmensen, C.; Kovatcheva-Datchary, P.; Myronovych, A.; Karns, R.; Wilson-Pérez, H.E.; Sandoval, D.A.; Kohli, R.; Bäckhed, F. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014, 509, 183–188.
123. Turnbaugh, P.J.; Ley, R.E.; Mahowald, M.A.; Magrini, V.; Mardis, E.R.; Gordon, J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444, 1027–1131.
124. Ridaura, V.K.; Faith, J.J.; Rey, F.E.; Cheng, J.; Duncan, A.E.; Kau, A.L.; Griffin, N.W.; Lombard, V.; Henrissat, B.; Bain, J.R.; et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013, 341, 1241214.
125. Vrieze, A.; Out, C.; Fuentes, S.; Jonker, L.; Reuling, I.; Kootte, R.S.; van Nood, E.; Holleman, F.; Knaapen, M.; Romijn, J.A. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J. Hepatol. 2014, 60, 824–831.
126. Karlsson, F.H.; Fak, F.; Nookaew, I.; Tremaroli, V.; Fagerberg, B.; Petranovic, D.; Backhed, F.; Nielsen, J. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nature commun. 2012, 3, 1245.
127. Tang, W.H.; Wang, Z.; Levison, B.S.; Koeth, R.A.; Britt, E.B.; Fu, X.; Wu, Y.; Hazen, S.L. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. New Engl. J. Med. 2013, 368, 1575–1584.
128. Zhong, C.Y.; Sun, W.W.; Ma, Y.; Zhu, H.; Yang, P.; Wei, H.; Zeng, B.H.; Zhang, Q.; Liu, Y.; Li, W.X.; et al. Microbiota prevents cholesterol loss from the body by regulating host gene expression in mice. Sci. Rep. 2015, 5, 10512.
129. Wilson, J.D. The quantification of cholesterol excretion and degradation in the isotopic steady state in the rat: The influence of dietary cholesterol. J. Lipid Res. 1964, 5, 409–417.
130. Wostmann, B.S.; Wiech, N.L.; Kung, E. Catabolism and elimination of cholesterol in germfree rats. J. Lipid Res 1966, 7, 77–82.
131. Jones, M.L.; Tomaro-Duchesneau, C.; Martoni, C.J.; Prakash, S. Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. Expert Opin. Biol. Ther. 2013, 13, 631–642.
132. McFarland, L.V. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: A systematic review. BMJ Open 2014, 4, doi:10.1136/bmjopen-2014-005047.
133. Tanaka, H.; Doesburg, K.; Iwasaki, T.; Mierau, I. Screening of lactic acid bacteria for bile salt hydrolase activity. Journal of dairy science 1999, 82, 2530–2535.
134. Begley, M.; Hill, C.; Gahan, C.G. Bile salt hydrolase activity in probiotics. Appl. Environ. Microbiol. 2006, 72, 1729–1738.
135. Duboc, H.; Rainteau, D.; Rajca, S.; Humbert, L.; Farabos, D.; Maubert, M.; Grondin, V.; Jouet, P.; Bouhassira, D.; Seksik, P.; et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 2012, 24, 513–520.
136. Ghouri, Y.A.; Richards, D.M.; Rahimi, E.F.; Krill, J.T.; Jelinek, K.A.; DuPont, A.W. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin. Exp. Gastroenterol. 2014, 7, 473–487.
137. Saez-Lara, M.J.; Gomez-Llorente, C.; Plaza-Diaz, J.; Gil, A. The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: A systematic review of randomized human clinical trials. Bio. Med. Res. Int. 2015, 2015, doi:10.1155/2015/505878.
138. Stojancevic, M.; Stankov, K.; Mikov, M. The impact of farnesoid x receptor activation on intestinal permeability in inflammatory bowel disease. Can. J. Gastroenterol. 2012, 26, 631–637.
139. Van Schaik, F.D.; Gadaleta, R.M.; Schaap, F.G.; van Mil, S.W.; Siersema, P.D.; Oldenburg, B.; van Erpecum, K.J. Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent crohn’s colitis. PloS ONE 2012, 7, doi:10.1371/journal. pone.0049706.
140. Jones, M.L.; Martoni, C.J.; Prakash, S. Letter to the editor regarding the report of duboc et al: Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease. Gut 2013, 62, 654–655.
141. Jones, M.L.; Martoni, C.J.; Prakash, S. Cholesterol lowering and inhibition of sterol absorption by lactobacillus reuteri ncimb 30242: A randomized controlled trial. Eur. J. Clin. Nutr. 2012, 66, 1234–1241.
142. Pavlovic, N.; Stankov, K.; Mikov, M. Probiotics—Interactions with bile acids and impact on cholesterol metabolism. Appl. Biochem. Biotechnol. 2012, 168, 1880–1895.
143. Hofmann, A.F. The function of bile salts in fat absorption. The solvent properties of dilute micellar solutions of conjugated bile salts. Biochem. J. 1963, 89, 57–68.
144. Angelakis, E.; Merhej, V.; Raoult, D. Related actions of probiotics and antibiotics on gut microbiota and weight modification. Lancet. Infect. Dis. 2013, 13, 889–899.
145. Sipka, S.; Bruckner, G. The immunomodulatory role of bile acids. Int. Arch. Allergy Immunol. 2014, 165, 1–8.